HDL Dysfunction in Diabetes: Causes and Possible Treatments

Overview

Journal Expert Rev Cardiovasc Ther

Specialty Cardiology & Vascular Diseases

Date 2012 Mar 7

PMID 22390807

Citations 77

Authors

Dan Farbstein

Andrew P Levy

Affiliations

Soon will be listed here.

Abstract

HDL is known to be inversely correlated with cardiovascular disease due to its diverse antiatherogenic functions. These functions include cholesterol efflux and reverse cholesterol transport, antioxidative and anti-inflammatory activities. However, HDL has been shown to undergo a loss of function in several pathophysiological states, as in the acute phase response, obesity and chronic inflammatory diseases. Some of these diseases were also shown to be associated with increased risk for cardiovascular disease. One such disease that is associated with HDL dysfunction and accelerated atherosclerosis is diabetes mellitus, a disease in which the HDL particle undergoes diverse structural modifications that result in significant changes in its function. This review will summarize the changes that occur in HDL in diabetes mellitus and how these changes lead to HDL dysfunction. Possible treatments for HDL dysfunction are also briefly described.

Citing Articles

Deciphering the Association: Critical HDL-C Levels and Their Impact on the Glycation Gap in People Living with HIV.

Anaya-Ambriz E, Alvarez-Zavala M, Gonzalez-Hernandez L, Andrade-Villanueva J, Zuniga-Quinones S, Valle-Rodriguez A Int J Mol Sci. 2025; 26(3).

PMID: 39940683 PMC: 11817432. DOI: 10.3390/ijms26030914.

Achillea millefolium capsule improved liver enzymes and lipid profile compared to placebo in patients with type 2 diabetes: a double-blind randomized clinical trial.

Daneshvar-Ghahfarokhi S, Ahmadinia H, Sadeghi T, Basirat E, Mohammadi-Shahrokhi V BMC Nutr. 2025; 11(1):21.

PMID: 39856724 PMC: 11761196. DOI: 10.1186/s40795-025-01005-5.

Systematic review and meta-analysis assessing the status of carotid intima-media thickness and lipid profiles in type 2 diabetes mellitus.

Mashaba R, Phoswa W, Maimela E, Lebelo S, Modjadji P, Mokgalaboni K BMJ Open. 2024; 14(11):e087496.

PMID: 39521468 PMC: 11552583. DOI: 10.1136/bmjopen-2024-087496.

ANGPTL3 as a target for treating lipid disorders in type 2 diabetes patients.

Chen J, Luo Q, Yi Y, Wang J, Chen P, Luo F Lipids Health Dis. 2024; 23(1):356.

PMID: 39487451 PMC: 11528995. DOI: 10.1186/s12944-024-02352-1.

Patterns of Lipid Abnormalities in Obesity: A Comparative Analysis in Normoglycemic and Prediabetic Obese Individuals.

Alshuweishi Y, Almufarrih A, Abudawood A, Alfayez D, Alkhowaiter A, AlSudais H J Pers Med. 2024; 14(9).

PMID: 39338234 PMC: 11432951. DOI: 10.3390/jpm14090980.

References

Glass C, Witztum J . Atherosclerosis. the road ahead. Cell. 2001; 104(4):503-16. DOI: 10.1016/s0092-8674(01)00238-0. View

Clark R, Sutfin T, Ruggeri R, Willauer A, Sugarman E, Magnus-Aryitey G . Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004; 24(3):490-7. DOI: 10.1161/01.ATV.0000118278.21719.17. View

Rothblat G, Phillips M . High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol. 2010; 21(3):229-38. PMC: 3215082. DOI: 10.1097/mol.0b013e328338472d. View

Alwaili K, Bailey D, Awan Z, Bailey S, Ruel I, Hafiane A . The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta. 2011; 1821(3):405-15. DOI: 10.1016/j.bbalip.2011.07.013. View

Watson C, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, Chang I . Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res. 2010; 52(2):361-73. PMC: 3023557. DOI: 10.1194/jlr.M011098. View

Goulinet S, Chapman M . Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Arterioscler Thromb Vasc Biol. 1997; 17(4):786-96. DOI: 10.1161/01.atv.17.4.786. View

Kontush A, Chapman M . Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol. 2010; 21(4):312-8. DOI: 10.1097/MOL.0b013e32833bcdc1. View

Nobecourt E, Davies M, Brown B, Curtiss L, Bonnet D, Charlton F . The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia. 2007; 50(3):643-53. DOI: 10.1007/s00125-006-0574-z. View

Shao B, Tang C, Heinecke J, Oram J . Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J Lipid Res. 2010; 51(7):1849-58. PMC: 2882738. DOI: 10.1194/jlr.M004085. View

10.

Grinshtein N, Bamm V, Tsemakhovich V, Shaklai N . Mechanism of low-density lipoprotein oxidation by hemoglobin-derived iron. Biochemistry. 2003; 42(23):6977-85. DOI: 10.1021/bi020647r. View

11.

DAgostino Sr R, Vasan R, Pencina M, Wolf P, Cobain M, Massaro J . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117(6):743-53. DOI: 10.1161/CIRCULATIONAHA.107.699579. View

12.

Shao B, Bergt C, Fu X, Green P, Voss J, Oda M . Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J Biol Chem. 2004; 280(7):5983-93. DOI: 10.1074/jbc.M411484200. View

13.

McGillicuddy F, de la Llera Moya M, Hinkle C, Joshi M, Chiquoine E, Billheimer J . Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009; 119(8):1135-45. PMC: 4937877. DOI: 10.1161/CIRCULATIONAHA.108.810721. View

14.

Bergt C, Pennathur S, Fu X, Byun J, OBrien K, McDonald T . The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A. 2004; 101(35):13032-7. PMC: 516512. DOI: 10.1073/pnas.0405292101. View

15.

Lewis G, Murdoch S, Uffelman K, Naples M, Szeto L, Albers A . Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone. Diabetes. 2004; 53(11):2893-900. DOI: 10.2337/diabetes.53.11.2893. View

16.

de Beer M, Durbin D, Cai L, Mirocha N, Jonas A, Webb N . Apolipoprotein A-II modulates the binding and selective lipid uptake of reconstituted high density lipoprotein by scavenger receptor BI. J Biol Chem. 2001; 276(19):15832-9. DOI: 10.1074/jbc.M100228200. View

17.

Nissen S, Tardif J, Nicholls S, Revkin J, Shear C, Duggan W . Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007; 356(13):1304-16. DOI: 10.1056/NEJMoa070635. View

18.

Spagnuolo M, Cigliano L, DAndrea L, Pedone C, Abrescia P . Assignment of the binding site for haptoglobin on apolipoprotein A-I. J Biol Chem. 2004; 280(2):1193-8. DOI: 10.1074/jbc.M411390200. View

19.

Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y . Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol. 2007; 28(2):341-7. DOI: 10.1161/ATVBAHA.107.153965. View

20.

Duell P, Bierman E . High glucose levels do not directly impair cellular binding of HDL3 or HDL-mediated efflux of cholesterol from human skin fibroblasts. Acta Diabetol. 1991; 28(2):174-8. DOI: 10.1007/BF00579722. View